PubRank

M A Caligiuri

Author PubWeight™ 241.84‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999 83.27
2 A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994 21.59
3 The biology of human natural killer-cell subsets. Trends Immunol 2001 10.10
4 Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 2000 8.58
5 Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 2001 5.23
6 Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 1994 5.20
7 Interleukin 15: biology and relevance to human disease. Blood 2001 4.47
8 Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res 2001 3.66
9 Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies. Hum Mol Genet 2001 3.58
10 Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J Immunol 1999 3.18
11 Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics. Proc Natl Acad Sci U S A 2001 3.01
12 Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells. J Exp Med 2001 2.96
13 Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Blood 1996 2.62
14 A potential role for interleukin-15 in the regulation of human natural killer cell survival. J Clin Invest 1997 2.37
15 The partial tandem duplication of ALL1 (MLL) is consistently generated by Alu-mediated homologous recombination in acute myeloid leukemia. Proc Natl Acad Sci U S A 1998 1.79
16 ALL-1 partial duplication in acute leukemia. Proc Natl Acad Sci U S A 1994 1.74
17 Human natural killer cell adhesion molecules. Differential expression after activation and participation in cytolysis. J Immunol 1990 1.74
18 Endogenous production of interleukin 15 by activated human monocytes is critical for optimal production of interferon-gamma by natural killer cells in vitro. J Clin Invest 1995 1.71
19 Identification of a gene at 11q23 encoding a guanine nucleotide exchange factor: evidence for its fusion with MLL in acute myeloid leukemia. Proc Natl Acad Sci U S A 2000 1.69
20 Natural killer cells from HIV-1+ patients produce C-C chemokines and inhibit HIV-1 infection. J Immunol 1998 1.59
21 Differential expression and function of L-selectin on CD56bright and CD56dim natural killer cell subsets. J Immunol 1998 1.55
22 Minimal region of loss at 13q14 in B-cell chronic lymphocytic leukemia. Blood 1996 1.54
23 ALL-1 tandem duplication in acute myeloid leukemia with a normal karyotype involves homologous recombination between Alu elements. Cancer Res 1994 1.52
24 Flt3 ligand promotes the generation of a distinct CD34(+) human natural killer cell progenitor that responds to interleukin-15. Blood 1998 1.51
25 Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia. Blood 1996 1.49
26 BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia. Proc Natl Acad Sci U S A 2001 1.48
27 Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells. Eur J Immunol 2001 1.46
28 Expression of a functional c-kit receptor on a subset of natural killer cells. J Exp Med 1993 1.45
29 Leukemia-associated Rho guanine nucleotide exchange factor, a Dbl family protein found mutated in leukemia, causes transformation by activation of RhoA. J Biol Chem 2001 1.39
30 The c-kit ligand suppresses apoptosis of human natural killer cells through the upregulation of bcl-2. Proc Natl Acad Sci U S A 1994 1.33
31 The functional characterization of interleukin-10 receptor expression on human natural killer cells. Blood 1995 1.26
32 Human natural killer cells produce abundant macrophage inflammatory protein-1 alpha in response to monocyte-derived cytokines. J Clin Invest 1996 1.23
33 Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol 2001 1.20
34 Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood 2000 1.20
35 Activating mutations in NOTCH1 in acute myeloid leukemia and lineage switch leukemias. Leukemia 2006 1.19
36 Fatal leukemia in interleukin-15 transgenic mice. Blood Cells Mol Dis 2001 1.17
37 Coadministration of interleukin-18 and interleukin-12 induces a fatal inflammatory response in mice: critical role of natural killer cell interferon-gamma production and STAT-mediated signal transduction. Blood 2000 1.15
38 Tumor cell apoptosis, lymphocyte recruitment and tumor vascular changes are induced by low temperature, long duration (fever-like) whole body hyperthermia. J Cell Physiol 1998 1.15
39 Expression and function of CD40 on Hodgkin and Reed-Sternberg cells and the possible relevance for Hodgkin's disease. Blood 1994 1.12
40 Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia. Leukemia 2012 1.11
41 Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay. Leukemia 1998 1.11
42 CD56bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand. Eur J Immunol 1997 1.10
43 Identification and characterization of an activating TrkA deletion mutation in acute myeloid leukemia. Mol Cell Biol 2000 1.10
44 Interleukin-1beta costimulates interferon-gamma production by human natural killer cells. Eur J Immunol 2001 1.09
45 Receptors for interleukin (IL)-10 and IL-6-type cytokines use similar signaling mechanisms for inducing transcription through IL-6 response elements. J Biol Chem 1996 1.07
46 Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720. Leukemia 2011 1.05
47 A fatal cytokine-induced systemic inflammatory response reveals a critical role for NK cells. J Immunol 1999 1.05
48 Characterization of interleukin-10 receptor expression on B-cell chronic lymphocytic leukemia cells. Blood 1997 1.04
49 Cutting edge: IL-15 costimulates the generalized Shwartzman reaction and innate immune IFN-gamma production in vivo. J Immunol 2000 1.02
50 Novel methylation targets in de novo acute myeloid leukemia with prevalence of chromosome 11 loci. Blood 2001 1.01
51 Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy. J Clin Invest 2000 1.01
52 Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing. Cancer Immunol Immunother 1998 0.99
53 Cytokine-induced apoptosis of human natural killer cells identifies a novel mechanism to regulate the innate immune response. Blood 1997 0.99
54 Differential expression of CD8 alpha and CD8 beta associated with MHC-restricted and non-MHC-restricted cytolytic effector cells. Cell Immunol 1990 0.98
55 Restriction landmark genome scanning for aberrant methylation in primary refractory and relapsed acute myeloid leukemia; involvement of the WIT-1 gene. Oncogene 1999 0.98
56 Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity. Blood 1995 0.98
57 A review of the association between interleukin-10 and human B-cell malignancies. Cancer Immunol Immunother 1998 0.97
58 A stem cell-like gene expression signature associates with inferior outcomes and a distinct microRNA expression profile in adults with primary cytogenetically normal acute myeloid leukemia. Leukemia 2013 0.95
59 Induction of natural killer effectors from human thymus with recombinant IL-2. J Immunol 1988 0.94
60 Low-dose interleukin 2 prevents the development of Epstein-Barr virus (EBV)-associated lymphoproliferative disease in scid/scid mice reconstituted i.p. with EBV-seropositive human peripheral blood lymphocytes. Proc Natl Acad Sci U S A 1994 0.94
61 Immunotherapy with low-dose interleukin-2: rationale for prevention of immune-deficiency-associated cancer. Cancer J Sci Am 1997 0.94
62 Ultra low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies. J Clin Invest 1998 0.93
63 Interleukin-15 as a potential regulator of the innate immune response. Braz J Med Biol Res 1998 0.89
64 An arrayed human not I-EcoRV boundary library as a tool for RLGS spot analysis. DNA Res 1997 0.89
65 The MLL partial tandem duplication in adults aged 60 years and older with de novo cytogenetically normal acute myeloid leukemia. Leukemia 2012 0.89
66 Molecular and clinical advances in core binding factor primary acute myeloid leukemia: a paradigm for translational research in malignant hematology. Cancer Invest 2000 0.89
67 Costimulation of human natural killer cells is required for interferon gamma production. Transplant Proc 1999 0.88
68 Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia. Leukemia 2001 0.88
69 GM-CSF and IL-2 induce specific cellular immunity and provide protection against Epstein-Barr virus lymphoproliferative disorder. J Clin Invest 2001 0.88
70 Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target. Leukemia 2013 0.87
71 Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicity. Clin Cancer Res 1996 0.87
72 A phase I/II study of rituximab and etanercept in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma. Leukemia 2009 0.87
73 Core-binding factor (CBF) and MLL-associated primary acute myeloid leukemia: biology and clinical implications. Ann Hematol 1999 0.86
74 The c-kit ligand potentiates the allogeneic mixed lymphocyte reaction. Blood 1996 0.85
75 Stem cell factor enhances interleukin-2-mediated expansion of murine natural killer cells in vivo. Blood 1997 0.84
76 Autoimmune pancytopenia following allogeneic bone marrow transplantation. Bone Marrow Transplant 1990 0.84
77 Ontogeny and expansion of human natural killer cells: clinical implications. Int Rev Immunol 2001 0.83
78 Interleukin 15: a potential player during the innate immune response to infection. Exp Parasitol 1996 0.83
79 The partial nontandem duplication of the MLL (ALL1) gene is a novel rearrangement that generates three distinct fusion transcripts in B-cell acute lymphoblastic leukemia. Cancer Res 2001 0.82
80 Acute nonlymphocytic leukemia in a glue sniffer. Am J Hematol 1985 0.82
81 High affinity interleukin-3 receptor expression on blasts from patients with acute myelogenous leukemia correlates with cytotoxicity of a diphtheria toxin/IL-3 fusion protein. Leuk Res 2001 0.82
82 Toward personalized therapy in AML: in vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML. Leukemia 2013 0.82
83 A role for IL-15 in rheumatoid arthritis? Nat Med 1998 0.81
84 Diabetes mellitus induced by low-dose interleukin-2. Cancer Immunol Immunother 1996 0.81
85 Endogenous CD8+ T cell expansion during regression of monoclonal EBV-associated posttransplant lymphoproliferative disorder. J Immunol 1999 0.79
86 Effects of antibody concentration on the separation of human natural killer cells in a commercial immunomagnetic separation system. Cytometry 2001 0.79
87 Description of an efficient and highly informative method for the evaluation of hematopoietic chimerism following allogeneic bone marrow transplantation. Bone Marrow Transplant 1995 0.79
88 Detection of unique ALL1 (MLL) fusion transcripts in normal human bone marrow and blood: distinct origin of normal versus leukemic ALL1 fusion transcripts. Cancer Res 1998 0.79
89 In situ determination of T-cell receptor beta expression patterns. J Histochem Cytochem 2001 0.79
90 Introduction: acute leukemia: recent advances. Semin Oncol 1997 0.78
91 Phenotypic and functional analysis of Fas (CD95) expression in primary central nervous system lymphoma of patients with acquired immunodeficiency syndrome. Blood 1997 0.77
92 Developments in cytogenetics and oncogenes in acute leukemia. Curr Opin Oncol 1997 0.77
93 Immunologic manipulation in AML: from bench to bedside. Leukemia 2002 0.77
94 G3139, a BCL-2 antisense oligo-nucleotide, in AML. Ann Hematol 2004 0.77
95 Natural killer cells: biology and application in stem-cell transplantation. Cytotherapy 2002 0.76
96 Cytokine replacement in patients with HIV-1 non-Hodgkin's lymphoma: the rationale for low-dose interleukin-2 therapy. Cancer J Sci Am 2000 0.76
97 Defining the "absence" of the CBFbeta/MYH11 fusion transcript in patients with acute myeloid leukemia and inversion of chromosome 16 to predict long-term complete remission: a call for definitions. Blood 1997 0.75
98 Expression of the zeta protein subunit in CD3- NK effectors derived from human thymus. Cell Immunol 1994 0.75
99 Prolonged diving and recovery in the freshwater turtle, Pseudemys scripta--IV. Effects of profound acidosis on O2 consumption in turtle vs rat (mammalian) brain and heart slices. Comp Biochem Physiol A Comp Physiol 1985 0.75
100 Acquired immunodeficiency syndrome-related lymphomas: future directions. Semin Oncol 2000 0.75
101 High-dose cytosine arabinoside in relapsed and refractory non-Hodgkin's lymphoma. Limited role as a single agent. Cancer 1989 0.75
102 Immune-mediated cytopenia following bone marrow transplantation. Case reports and review of the literature. Medicine (Baltimore) 1992 0.75
103 Cytokines in the evolution and treatment of AIDS-lymphoma. Curr Opin Oncol 1999 0.75